Baxter International and Takeda Pharmaceutical Co. Ltd. have entered a development, license and technology transfer agreement to bring Vero cell culture-based influenza vaccines to the Japanese market. Takeda will exclusively license Baxter’s Vero cell-based flu vaccine technology and the companies will jointly pursue development and licensure of an H5N1 flu vaccine in Japan. Baxter will assist Takeda in obtaining funding from the Japanese government for the construction of a manufacturing fa...